IN8bio Inc

NASDAQ:INAB  
3.25
-0.08 (-2.40%)
Products, Regulatory

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

Published: 12/16/2021 12:24 GMT
IN8bio Inc (INAB) - In8bio Provides Update From the Ongoing Phase 1 Clinical Trial of Its Allogeneic Gamma-delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant.
In8bio, Inc. - of 3 Patients That Were Dosed With Inb-100, All Have Achieved and Remain in Remission to Date.
In8bio, Inc. - Inb-100 Continues to Demonstrate a Manageable Safety Profile To-date.